Skip to main content

HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.

Publication ,  Journal Article
Verkoczy, L; Kelsoe, G; Haynes, BF
Published in: PLoS Pathog
May 2014

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

PLoS Pathog

DOI

EISSN

1553-7374

Publication Date

May 2014

Volume

10

Issue

5

Start / End Page

e1004073

Location

United States

Related Subject Headings

  • Virology
  • Mutation
  • Immune Tolerance
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Envelope Protein gp41
  • HIV Antibodies
  • Drug Discovery
  • Autoantibodies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Verkoczy, L., Kelsoe, G., & Haynes, B. F. (2014). HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog, 10(5), e1004073. https://doi.org/10.1371/journal.ppat.1004073
Verkoczy, Laurent, Garnett Kelsoe, and Barton F. Haynes. “HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.PLoS Pathog 10, no. 5 (May 2014): e1004073. https://doi.org/10.1371/journal.ppat.1004073.
Verkoczy L, Kelsoe G, Haynes BF. HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog. 2014 May;10(5):e1004073.
Verkoczy, Laurent, et al. “HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.PLoS Pathog, vol. 10, no. 5, May 2014, p. e1004073. Pubmed, doi:10.1371/journal.ppat.1004073.
Verkoczy L, Kelsoe G, Haynes BF. HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog. 2014 May;10(5):e1004073.

Published In

PLoS Pathog

DOI

EISSN

1553-7374

Publication Date

May 2014

Volume

10

Issue

5

Start / End Page

e1004073

Location

United States

Related Subject Headings

  • Virology
  • Mutation
  • Immune Tolerance
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Envelope Protein gp41
  • HIV Antibodies
  • Drug Discovery
  • Autoantibodies